PerkinElmer this week reported that fourth-quarter revenues rose 20 percent, fueled by strong growth in its Life and Analytical Sciences segments. The company also said profits for the period climbed 26 percent.
 
President and newly-elected CEO Robert Friel said the company is “seeing more growth on the reagent side than the instrument side,” and as a result will “continue to drive new products particularly into the reagent area … particularly into our cell-based assays and GPCR screening.”

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.